{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:25:55Z","timestamp":1773419155558,"version":"3.50.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2001,6,1]],"date-time":"2001-06-01T00:00:00Z","timestamp":991353600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2001,6]]},"DOI":"10.1007\/s11906-001-0045-3","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T02:02:26Z","timestamp":1180058546000},"page":"230-239","source":"Crossref","is-referenced-by-count":32,"title":["Primary aldosteronism: Rare bird or common cause of secondary hypertension?"],"prefix":"10.1007","volume":"3","author":[{"given":"Michael","family":"Stowasser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"45_CR1","first-page":"6","volume":"45","author":"JW Conn","year":"1955","unstructured":"Conn JW: Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955, 45:6\u201317.","journal-title":"J Lab Clin Med"},{"key":"45_CR2","first-page":"865","volume-title":"Textbook of Hypertension","author":"RD Gordon","year":"1994","unstructured":"Gordon RD, Stowasser M, Klemm SA, Tunny TJ: Primary aldosteronism and other forms of mineralocorticoid hypertension. In Textbook of Hypertension. Edited by Swales JD. London: Blackwell Scientific; 1994:865\u2013892."},{"key":"45_CR3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00045415-199907000-00012","volume":"7","author":"WF Young Jr","year":"1999","unstructured":"Young WF Jr: Primary aldosteronism: a common and curable form of hypertension. Cardiol Rev 1999, 7:207\u2013214. An excellent review of the clinical features, familial varieties, diagnostic work-up, and management of PAL. Improved screening methodologies were associated with a more than 10-fold increase in the average annual rate of diagnosis of PAL at the Mayo Clinic for the previous 8 years, compared with the period between 1960 and 1991.","journal-title":"Cardiol Rev"},{"key":"45_CR4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/sj.jhh.1001013","volume":"14","author":"PO Lim","year":"2000","unstructured":"Lim PO, Dow E, Brennan G, et al.: High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000, 14:311\u2013315. Aldosterone\/PRA ratio levels were elevated in 77 (15.5%) of 495 consecutive patients referred to a hypertension unit in Dundee, UK. PAL was confirmed in 43 of the 45 patients who were assessed further by salt loading and fludrocortisone suppression tests or who had an APA removed, suggesting the plasma aldosterone to PRA ratio to be highly specific for PAL in these workers\u2019 hands.","journal-title":"J Hum Hypertens"},{"key":"45_CR5","first-page":"394","volume":"90","author":"BL Rayner","year":"2000","unstructured":"Rayner BL, Opie LH, Davidson JS: The aldosterone\/renin ratio as a screening test for primary aldosteronism. S Afr Med J 2000, 90:394\u2013400.","journal-title":"S Afr Med J"},{"key":"45_CR6","first-page":"1863","volume":"85","author":"CE Fardella","year":"2000","unstructured":"Fardella CE, Mosso L, Gomez-Sanchez C, et al.: Primary aldosteronism in essential hypertensives: prevalence, biochemical profile and molecular biology. J Clin Endocrinol Metab 2000, 85:1863\u20131867. A carefully performed study in which PAL (normokalemic in each case) was confirmed among patients with a high aldosterone\/PRA ratio by FST in 29 (9.5%) of 305 hypertensives and three (1.5%) of 205 normotensives. Among those with PAL, three (two hypertensive, one normotensive) had FH-I confirmed by long PCR testing of peripheral blood DNA.","journal-title":"J Clin Endocrinol Metab"},{"key":"45_CR7","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.1964.03070160046009","volume":"190","author":"JW Conn","year":"1964","unstructured":"Conn JW: Plasma renin activity in primary aldosteronism. Importance in differential diagnosis and in research of essential hypertension. JAMA 1964, 190:222\u2013225.","journal-title":"JAMA"},{"key":"45_CR8","first-page":"201","volume":"90","author":"JJ Brown","year":"1964","unstructured":"Brown JJ, Davies DL, Lever AF, Robertson JIS: Variations in plasma renin concentration in several physiological and pathological states. Can Med Assoc J 1964, 90:201\u2013206.","journal-title":"Can Med Assoc J"},{"key":"45_CR9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/0021-9681(58)90051-1","volume":"8","author":"AH Shamma","year":"1958","unstructured":"Shamma AH, Goddard JW, Sommers SC: Study of adrenal status in hypertension. J Chronic Dis 1958, 8:587\u2013595.","journal-title":"J Chronic Dis"},{"key":"45_CR10","first-page":"257","volume":"62","author":"JW Conn","year":"1968","unstructured":"Conn JW: The evolution of primary aldosteronism: 1954\u20131967. Harvey Lect 1968, 62:257\u2013291.","journal-title":"Harvey Lect"},{"key":"45_CR11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/archinte.1969.00300120001001","volume":"123","author":"JW Conn","year":"1969","unstructured":"Conn JW, Rovner DR, Cohen EL, et al.: Preoperative diagnosis of primary aldosteronism. Including a comparison of operative findings and preoperative tumour localization by adrenal phlebography. Arch Intern Med 1969, 123:113\u2013123.","journal-title":"Arch Intern Med"},{"key":"45_CR12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1440-1681.1991.tb01446.x","volume":"18","author":"RD Gordon","year":"1991","unstructured":"Gordon RD, Stowasser M, Tunny TJ, et al.: Clinical and pathological diversity of primary aldosteronism including a new familial variety. Clin Exp Pharmacol Physiol 1991, 18:283\u2013286.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"45_CR13","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1210\/jcem-73-5-952","volume":"73","author":"TJ McKenna","year":"1991","unstructured":"McKenna TJ, Sequeira SJ, Heffernan A, et al.: Diagnosis under random conditions of all disorders of the renin-angiotensinaldosterone axis, including primary aldosteronism. J Clin Endocrinol Metab 1991, 73:952\u2013957.","journal-title":"J Clin Endocrinol Metab"},{"key":"45_CR14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/archinte.1969.00300120040006","volume":"123","author":"NM Kaplan","year":"1969","unstructured":"Kaplan NM: Commentary on the incidence of primary aldosteronism. Current estimations based on objective data. Arch Intern Med 1969, 123:152\u2013155.","journal-title":"Arch Intern Med"},{"key":"45_CR15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1161\/01.RES.18.S6.I-158","volume":"18","author":"JH Laragh","year":"1966","unstructured":"Laragh JH, Sealey JE, Sommers SC: Patterns of adrenal secretion and urinary excretion of aldosterone and plasma renin activity in normal and hypertensive subjects. Circ Res 1966, 18:158\u2013174.","journal-title":"Circ Res"},{"key":"45_CR16","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/jama.1968.03140330039007","volume":"205","author":"LM Fishman","year":"1968","unstructured":"Fishman LM, K\u00fcchel O, Liddle GW, et al.: Incidence of primary aldosteronism uncomplicated \"essential\" hypertension. JAMA 1968, 205:497\u2013502.","journal-title":"JAMA"},{"key":"45_CR17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.0954-6820.1981.tb02620.x","volume":"646","author":"JO Lund","year":"1981","unstructured":"Lund JO, Nielsen D, Giese J: Prevalence of primary aldosteronism. Acta Med Scand 1981, 646(suppl):54\u201357.","journal-title":"Acta Med Scand"},{"key":"45_CR18","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/bmj.2.6035.554","volume":"2","author":"G Berglund","year":"1976","unstructured":"Berglund G, Andersson O, Wilhelmsen L: Prevalence of primary and secondary hypertension: studies in a random population. Br Med J 1976, 2:554\u2013556.","journal-title":"Br Med J"},{"key":"45_CR19","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/17843286.1974.11716942","volume":"29","author":"DG Beevers","year":"1974","unstructured":"Beevers DG, Nelson CS, Padfield PL, et al.: The prevalence of hypertension in an unselected population, and the frequency of abnormalities of potassium, angiotensin II and aldosterone in hypertensive subjects. Acta Clin Belg 1974, 29:276\u2013280.","journal-title":"Acta Clin Belg"},{"key":"45_CR20","first-page":"187","volume":"2","author":"GS Anderson","year":"1988","unstructured":"Anderson GS, Toftdahl DB, Lund JO, et al.: The incidence rate of phaeochromocytoma and Conns syndrome in Denmark, 1977\u20131981. J Hum Hypertens 1988, 2:187\u2013189.","journal-title":"J Hum Hypertens"},{"key":"45_CR21","first-page":"947","volume":"87","author":"MG Crane","year":"1976","unstructured":"Crane MG, Harris JJ: Effect of aging on renin activity and aldosterone excretion. J Lab Clin Med 1976, 87:947\u2013959.","journal-title":"J Lab Clin Med"},{"key":"45_CR22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM197203022860901","volume":"286","author":"HR Brunner","year":"1972","unstructured":"Brunner HR, Laragh JH, Baer L, et al.: Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972, 286:441\u2013449.","journal-title":"N Engl J Med"},{"key":"45_CR23","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/archinte.1981.00340130033011","volume":"141","author":"K Hiramatsu","year":"1981","unstructured":"Hiramatsu K, Yamada T, Yukimura Y, et al.: A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Arch Intern Med 1981, 141:1589\u20131593.","journal-title":"Arch Intern Med"},{"key":"45_CR24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/BF03349761","volume":"18","author":"RD Gordon","year":"1995","unstructured":"Gordon RD: Primary aldosteronism. J Endocrinol Invest 1995, 18:495\u2013511.","journal-title":"J Endocrinol Invest"},{"key":"45_CR25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/pgmj.75.882.235","volume":"75","author":"MJ Brown","year":"1999","unstructured":"Brown MJ, Hopper RV: Calcium-channel blockade can mask the diagnosis of Conn\u2019s syndrome. Postgrad Med J 1999, 75:235\u2013236.","journal-title":"Postgrad Med J"},{"key":"45_CR26","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1530\/acta.0.1130564","volume":"113","author":"PE Lins","year":"1986","unstructured":"Lins PE, Adamson U: Plasma aldosterone-plasma renin activity ratio: a simple test to identify patients with primary aldosteronism. Acta Endocrinol 1986, 113:564\u2013569.","journal-title":"Acta Endocrinol"},{"key":"45_CR27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1440-1681.1985.tb02641.x","volume":"12","author":"SM Hamlet","year":"1985","unstructured":"Hamlet SM, Tunny TJ, Woodland E, Gordon RD: Is aldosterone\/ renin ratio useful to screen a hypertensive population for primary aldosteronism? Clin Exp Pharmacol Physiol 1985, 12:249\u2013252.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"45_CR28","doi-asserted-by":"crossref","unstructured":"Stowasser M, Gordon RD: Prevalence and diagnostic workup of primary aldosteronism. Nephrology 2001, In press.","DOI":"10.1046\/j.1440-1797.2001.00040.x"},{"key":"45_CR29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1440-1681.1994.tb02519.x","volume":"21","author":"RD Gordon","year":"1994","unstructured":"Gordon RD, Stowasser M, Tunny TJ, et al.: High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994, 21:315\u2013318.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"45_CR30","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1440-1681.1993.tb01687.x","volume":"20","author":"RD Gordon","year":"1993","unstructured":"Gordon RD, Ziezak MD, Tunny TJ, et al.: Evidence that primary aldosteronism may not be uncommon- twelve percent incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993, 20:296\u2013298.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"45_CR31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(05)74868-6","volume":"353","author":"PO Lim","year":"1999","unstructured":"Lim PO, Rodgers P, Cardale K, et al.: Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 1999, 353:40. When these investigators applied the aldosterone\/PRA ratio to 125 hypertensive patients randomly selected from a UK family physician practice database, they found high levels in 18 (14.4%), most of whom probably had PAL.","journal-title":"Lancet"},{"key":"45_CR32","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1046\/j.1365-2125.1999.00070.x","volume":"48","author":"PO Lim","year":"1999","unstructured":"Lim PO, Jung RT, MacDonald TM: Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol 1999, 48:756\u2013760.","journal-title":"Br J Clin Pharmacol"},{"key":"45_CR33","doi-asserted-by":"crossref","first-page":"199A","DOI":"10.1016\/S0895-7061(97)91442-4","volume":"11","author":"AY Anwar","year":"1998","unstructured":"Anwar AY, White WB, Mansoor GA, Tendler BE: Hyperaldosteronism is a common cause of secondary hypertension missed by primary care physicians and associated with normokalemia [abstract]. Am J Hypertens 1998, 11:199A. Of 24 patients with refractory hypertension due to probable PAL (raised aldosterone\/renin ratio, and\/or elevated 24-hour urinary aldosterone values), only 54% were hypokalemic. Specific treatment (antialdosterone medication in 21, adrenalectomy in three) led to a substantial improvement in hypertension control.","journal-title":"Am J Hypertens"},{"issue":"suppl 1","key":"45_CR34","doi-asserted-by":"crossref","first-page":"83s","DOI":"10.1016\/S0753-3322(00)80019-0","volume":"54","author":"T Nishikawa","year":"2000","unstructured":"Nishikawa T, Omura M: Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother 2000, 54(suppl 1):83s-85s.","journal-title":"Biomed Pharmacother"},{"key":"45_CR35","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1365-2265.1998.00608.x","volume":"49","author":"GP Rossi","year":"1998","unstructured":"Rossi GP, Rossi E, Pavan E, et al.: Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol 1998, 49:713\u2013723.","journal-title":"Clin Endocrinol"},{"key":"45_CR36","first-page":"2854","volume":"85","author":"K-C Loh","year":"2000","unstructured":"Loh K-C, Koay ES, Khaw M-C, et al.: Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000, 85:2854\u20132859. In this carefully conducted study, the investigators found 63 (18%) of 350 hypertensives attending primary care clinics in Singapore to have elevated aldosterone\/PRA ratios, but ruled out PAL in many of them on the basis of saline infusion testing results, eventually estimating the prevalence of PAL to be approximately 5% in this population. They diagnosed approximately half of their patients with PAL as having APAs based on a combination of CT adrenal scanning and adrenal venous sampling.","journal-title":"J Clin Endocrinol Metab"},{"key":"45_CR37","first-page":"4031","volume":"84","author":"M Stowasser","year":"1999","unstructured":"Stowasser M, Taylor WL, Huggard PJ, et al.: Biochemical evidence of aldosterone overproduction and abnormal regulation in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 1999, 84:4031\u20134036. Biochemical evidence of excessive, adrenocorticotropic hormone-regulated aldosterone production and excessive 18-oxo-cortisol production was present in 10 individuals with FH-I who were normotensive.","journal-title":"J Clin Endocrinol Metab"},{"key":"45_CR38","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/00004872-200018090-00002","volume":"18","author":"M Stowasser","year":"2000","unstructured":"Stowasser M, Gordon RD: Primary aldosteronism: learning from the study of familial varieties. J Hypertens 2000, 18:1165\u20131176.","journal-title":"J Hypertens"},{"key":"45_CR39","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/355262a0","volume":"355","author":"RP Lifton","year":"1992","unstructured":"Lifton RP, Dluhy RG, Powers M, et al.: A chimaeric 11bhydroxylase\/ aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992, 355:262\u2013265.","journal-title":"Nature"},{"key":"45_CR40","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1006\/bbrc.1995.1225","volume":"207","author":"JR Jonsson","year":"1995","unstructured":"Jonsson JR, Klemm SA, Tunny TJ, et al.: A new genetic test for Familial Hyperaldosteronism Type I aids in the detection of curable hypertension. Biochem Biophys Res Comm 1995, 207:565\u2013571.","journal-title":"Biochem Biophys Res Comm"},{"key":"45_CR41","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1210\/jcem.83.7.4946","volume":"83","author":"P Mulatero","year":"1998","unstructured":"Mulatero P, Veglio F, Pilon C, et al.: Diagnosis of glucocorticoidremediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. J Clin Endocrinol Metab 1998, 83:2573\u20132575.","journal-title":"J Clin Endocrinol Metab"},{"key":"45_CR42","first-page":"299","volume":"41","author":"FA McAlister","year":"1998","unstructured":"McAlister FA, Lewanczuk RZ: Primary hyperaldosteronism and adrenal incidentaloma: an argument for physiological testing before adrenalectomy. Can J Surg 1998, 41:299\u2013305. Of 18 patients with PAL plus an adrenal mass visualized on CT, only 13 had APA subsequently proven by AVS. The remaining five patients had BAH.","journal-title":"Can J Surg"},{"issue":"suppl 5","key":"45_CR43","first-page":"S103","volume":"5","author":"RD Gordon","year":"1987","unstructured":"Gordon RD, Gomez-Sanchez CE, Hamlet SM, et al.:Angiotensin-responsive aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (IHA: adrenal hyperplasia) or low-renin essential hypertension. J Hypertens 1987, 5(suppl 5):S103-S106.","journal-title":"J Hypertens"},{"key":"45_CR44","first-page":"1771","volume":"A4","author":"S Ulick","year":"1982","unstructured":"Ulick S, Chu MD: Hypersecretion of a new corticosteroid, 18-hydroxycortisol in two types of adrenocortical hypertension. Clin Exp Hypertens 1982, A4:1771\u20131777.","journal-title":"Clin Exp Hypertens"},{"key":"45_CR45","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1445-5994.1997.tb00999.x","volume":"27","author":"M Stowasser","year":"1997","unstructured":"Stowasser M, Gartside MG, Gordon RD: A PCR-based method of screening individuals of all ages, from neonates to the elderly, for Familial Hyperaldosteronism Type I. Aust NZ J Med 1997, 27:685\u2013690.","journal-title":"Aust NZ J Med"},{"key":"45_CR46","first-page":"159","volume":"1","author":"F Fallo","year":"2000","unstructured":"Fallo F, Veglio F, Mulatero P, et al.: Genetic studies in familial aldosteronism not suppressible by dexamethasone. J Endocrinol Genet 2000, 1:159\u2013164. These authors found no evidence of the following among four patients with FH-II: 1) the hybrid gene mutation responsible for FH-I; 2) polymorphisms within the aldosterone synthase gene that have been implicated in aldosterone excess in humans; or 3) mutations within the 11b-hydroxylase gene that have been shown to confer aldosterone synthase activity to its gene product in vitro.","journal-title":"J Endocrinol Genet"},{"key":"45_CR47","first-page":"1633","volume":"84","author":"Y Takeda","year":"1999","unstructured":"Takeda Y, Furukawa K, Inaba S, et al.: Genetic analysis of aldosterone synthase in patients with idiopathic hyperaldosteronism. J Clin Endocrinol Metab 1999, 84:1633\u20131637.","journal-title":"J Clin Endocrinol Metab"},{"key":"45_CR48","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3109\/07435809809032702","volume":"24","author":"M Hampf","year":"1998","unstructured":"Hampf M, Widimsky J, Bernhardt R: Aldosterone synthase gene in patients suffering from hyperaldosteronism. Endocrinol Res 1998, 24:877\u2013880. Examination of the promoter region of CYP11B2 in DNA from patients with BAH revealed no evidence of mutations that might be responsible for PAL in those subjects.","journal-title":"Endocrinol Res"},{"key":"45_CR49","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1161\/01.HYP.33.2.703","volume":"33","author":"E Davies","year":"1999","unstructured":"Davies E, Holloway CD, Ingram MC, et al.: Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 1999, 33:703\u2013707.","journal-title":"Hypertension"},{"key":"45_CR50","unstructured":"Davies E: Variation at the aldosterone synthase gene locus (CYP11B2) in hypertension [abstract]. Paper presented at Cardiovascular Endocrinology and Metabolism, a Satellite Meeting to the International Congress of Endocrinology\u2019s Fourth Annual Meeting of the Society for Cardiovascular Endocrinology and Metabolism. October 27\u201329, 2000. Palm Grove, Queensland, Australia."},{"key":"45_CR51","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nsb0197-32","volume":"4","author":"KM Curnow","year":"1997","unstructured":"Curnow KM, Mulatero P, Emeric-Blanchouin N, et al.: The amino acid substitutions Ser288Gly and Val320Ala convert the cortisol producing enzyme, CYP11B1, into an aldosterone producing enzyme. Nat Struct Biol 1997, 4:32\u201335.","journal-title":"Nat Struct Biol"},{"key":"45_CR52","first-page":"4228","volume":"84","author":"C Pilon","year":"1999","unstructured":"Pilon C, Mulatero P, Barzon L, et al.: Mutations in CYP11B1 gene converting 11b-hydroxylase into an aldosteroneproducing enzyme are not present in aldosterone-producing adenomas. J Clin Endocrinol Metab 1999, 84:4228\u20134231.","journal-title":"J Clin Endocrinol Metab"},{"key":"45_CR53","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1440-1681.1995.tb02043.x","volume":"22","author":"SA Klemm","year":"1995","unstructured":"Klemm SA, Ballantine DM, Tunny TJ, et al.: PCR-SSCP analysis of the angiotensin II type 1 receptor gene in patients with aldosterone-producing adenomas. Clin Exp Pharmacol Physiol 1995, 22:457\u2013459.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"45_CR54","first-page":"611","volume":"82","author":"E Davies","year":"1997","unstructured":"Davies E, Bonnardeaux A, Plouin P-F, et al.: Somatic mutations of the angiotensin II (AT1) receptor gene are not present in aldosterone-producing adenoma. J Clin Endocrinol Metab 1997, 82:611\u2013615.","journal-title":"J Clin Endocrinol Metab"},{"key":"45_CR55","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1440-1681.1996.tb02786.x","volume":"23","author":"DM Ballantine","year":"1996","unstructured":"Ballantine DM, Klemm SA, Tunny TJ, et al.: PCR-SSCP analysis of the p53 gene in tumours of the adrenal gland. Clin Exp Pharmacol Physiol 1996, 23:582\u2013583.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"45_CR56","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/gcc.2870120114","volume":"12","author":"A Iida","year":"1995","unstructured":"Iida A, Blake K, Tunny T, et al.: Allelic losses on chromosome 11q13 in aldosterone-producing adrenal tumors. Genes Chromosomes Cancer 1995, 12:73\u201375.","journal-title":"Genes Chromosomes Cancer"},{"key":"45_CR57","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1440-1681.1996.tb02790.x","volume":"23","author":"RD Gordon","year":"1996","unstructured":"Gordon RD, Gartside M, Tunny TJ, Stowasser M: Different allelic patterns at chromosome 11q13 in paired aldosteroneproducing tumours and blood DNA. Clin Exp Pharmacol Physiol 1996, 23:594\u2013596.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"45_CR58","first-page":"1046","volume":"83","author":"DJ Torpy","year":"1998","unstructured":"Torpy DJ, Gordon RD, Stratakis CA: Linkage analysis of familial hyperaldosteronism type II - absence of linkage of the gene encoding the angiotensin II receptor type 1. J Clin Endocrinol Metab 1998, 83:1046.","journal-title":"J Clin Endocrinol Metab"},{"key":"45_CR59","first-page":"3214","volume":"83","author":"DJ Torpy","year":"1998","unstructured":"Torpy DJ, Gordon RD, Lin J-P, et al.: Familial hyperaldosteronism type-II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. J Clin Endocrinol Metab 1998, 83:3214\u20133218.","journal-title":"J Clin Endocrinol Metab"},{"key":"45_CR60","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/jmg.37.11.831","volume":"37","author":"AR Lafferty","year":"2000","unstructured":"Lafferty AR, Torpy DJ, Stowasser M, et al.: A novel locus for low-renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22). J Med Genet 2000, 37:831\u2013835. A genome-wide search involving a family of eight individuals (two of them normotensive) with FH-II demonstrated linkage with a locus within the telomeric end of the short arm of chromosome 7.","journal-title":"J Med Genet"},{"key":"45_CR61","first-page":"307","volume":"44","author":"GS McKnight","year":"1988","unstructured":"McKnight GS, Clegg CH, Uhler MD, et al.: Analysis of the cAMP-dependent protein kinase system using molecular genetic approaches. Recent Prog Horm Res 1988, 44:307\u2013335.","journal-title":"Recent Prog Horm Res"},{"key":"45_CR62","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/79238","volume":"26","author":"LS Kirschner","year":"2000","unstructured":"Kirschner LS, Carney JA, Pack SD, et al.: Mutations of the gene encoding the protein kinase A type 1-a regulatory subunit in patients with the Carney complex. Nat Genet 2000, 26:89\u201392.","journal-title":"Nat Genet"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-001-0045-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-001-0045-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-001-0045-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T14:10:32Z","timestamp":1707919832000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-001-0045-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["45"],"URL":"https:\/\/doi.org\/10.1007\/s11906-001-0045-3","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]}}}